- Bone Health
- Immunology
- Hematology
- Respiratory
- Dermatology
- Diabetes
- Gastroenterology
- Neurology
- Oncology
- Ophthalmology
- Rare Disease
- Rheumatology
Biosimilars Immunology Roundup for July 2023—Podcast Edition
On this episode, we’re giving a rundown of some of the biggest stories in the immunology space regarding biosimilars, like the launch of 7 adalimumab biosimilars, the release of multiple market trend reports, and clinical trial results on traditionally bypassed disease states.
On this episode, we’re giving a rundown of some of the biggest stories in the immunology space regarding biosimilars, like the launch of 7 adalimumab biosimilars, the release of multiple market trend reports, and clinical trial results on traditionally bypassed disease states.
Show Notes
First Round of Adalimumab Biosimilar Launches in July
Celltrion Launches Yuflyma on the US Market
US Welcomes Idacio, Hulio to the Adalimumab Biosimilar Market
Will the Entry of Adalimumab Biosimilars to the US Market Successfully Lower Spending?
Contributor: Self-Administered Biosimilars Are Coming Quickly—Is Your Clinic Ready?
Despite Steep Discounts, Humira Biosimilars Are Priced More Than Original Originator Price
Price Reductions of TNF Inhibitors Across Europe After First and Second Biosimilar Launches
Multiple Infliximab Biosimilar Switches Were Safe, Effective
Adalimumab Biosimilar Improved Symptoms for up to 48 Weeks in Ankylosing Spondylitis
Biosimilar, Innovator Romiplostim Comparably Safe and Effective
Insights from Festival of Biologics: Dracey Poore Discusses Cardinal Health’s 2024 Biosimilar Report
May 19th 2024The discussion highlights key emerging trends from the Festival of Biologics conference and the annual Cardinal Health Biosimilars Report, including the importance of sustainability in the health care landscape and the challenges and successes in biosimilar adoption and affordability.
Functional Similarity Between Ustekinumab Biosimilar ABP 654, Stelara in Crohn Disease
January 18th 2025Functional similarity of the ustekinumab biosimilar ABP 654 (Wezlana) and the reference product (Stelara) was confirmed by a series of in vitro studies, which support the totality of evidence for the biosimliar's FDA approval.
Decoding the Patent Puzzle: Navigating the Legal Landscape of Biosimilars
March 17th 2024On this episode of Not So Different, Ha Kung Wong, JD, an intellectual patent attorney and partner at Venable LLP, details the confusing landscape that is the US patent system and how it can be improved to help companies overcome barriers to biosimilar competition.
Cost-Efficiency in Action: Denmark's Transition to Biosimilar Adalimumab
January 14th 2025The nationwide mandatory switch from Humira (reference adalimumab) to biosimilar adalimumab in Denmark led to no increase in total health care costs over 9 months, with significant cost reductions for those who switched to GP2017 specifically, highlighting the economic feasibility of biosimilar adoption.
